XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

February 20th to 22nd, 2017 | Berlin | World ADC

Meet us at the 7th World ADC in Berlin. Lets talk about this high potential of new biopharmaceutical drugs represented by the Antibody Drug Conjugate and how preclinical studies can help you to develop and optimize them.Do you want to know more about this event ? See the official program. At this occasion, we will […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...